Diabetes drug metformin may echo the benefits of exercise in prostate cancer care

A new study has found that metformin, a widely prescribed diabetes drug, may mimic one of exercise's core biological effects in men with prostate cancer, raising levels of a molecule tied to energy balance and weight control even when patients are inactive. The findings suggest that metformin could help counter the metabolic strain of hormone therapy, when fatigue and other side effects often limit physical activity.